Investigational drug · Phase 2
INB301
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer Cachexia.
Phase 2Last checked: Nov 19, 2026Latest source record: May 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "INB301"
First trial start
2026
May 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INB301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer Cachexia
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INB301" as an intervention, largest first.
- An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer CachexiaNot yet recruiting
Yunnan Baiyao Group Co., Ltd.Industry
NCT07584057 · 146 participants (planned) · Start May 2026 · Primary completion Feb 2030
Drug: INB301 Injection · For: Cancer Cachexia
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cancer Cachexia
- JMT203Phase 21 trial
Shanghai JMT-Bio Inc. · Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia
- NGM120Phase 21 trial
NGM Biopharmaceuticals, Inc · Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
- QLS2319Phase 21 trial
Qilu Pharmaceutical Co., Ltd. · Cancer Cachexia, Cancer Cachexia Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.